Clayton, Dubilier & Rice, LLC completed its acquisition of Huntsworth PLC on May 1, 2020. The strategic rationale centers on Huntsworth’s position as a leading pharma commercialization services platform, with a strong Health division contributing roughly 85% of the group’s operating profit. CD&R views the company’s underlying markets as attractive, underpinned by long‑term healthcare trends such as demographic shifts, rising drug innovation, increasing outsourcing of commercial and medical services, and the growing complexity of marketing and access channels for specialized therapies. The investment aligns with CD&R’s healthcare‑focused strategy and experience with similar hybrid healthcare‑services models, including its prior involvement with platforms comparable to Huntsworth through former executives such as Liam FitzGerald, an operating advisor who assumed the role of Chairman. From a value‑creation standpoint, the transaction allows Huntsworth to pursue accelerated organic growth and targeted acquisitions without the constraints of public‑market volatility, while CD&R aims to strengthen operational discipline, deepen sector penetration, and broaden the group’s service offerings.

HUNTSWORTH, which reported an EBITDA margin of LOGIN in 2019, is valued in this transaction at an EV/EBITDA multiple of LOGIN, representing a LOGIN discount to the average currently observed in the Healthcare & Pharma sector (13.4x).

Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.